How large is the Swiss cannabis market?

TL;DR

• THC black market: estimated CHF 500 M–1 bn/year (ZHAW 2023).
• CBD market (legal <1 % THC): ~CHF 600 M (Cannalist 2024).
• Medical cannabis: ~CHF 15 M, growing fast since Aug 2022.
• Consumers: ~500 000 Swiss residents use THC regularly (Addiction Switzerland).

Market segments overview

• 1. THC black market — dominant, untaxed, no quality control.
• 2. Legal CBD market — flower, oils, cosmetics, vapes.
• 3. Medical cannabis — prescription-based via pharmacies.
• 4. Industrial hemp — textiles, construction, food.
• 5. Pilot project sales — regulated THC sales in six cities.

How to size the Swiss cannabis market properly – and why most figures fail

Any defensible Swiss market estimate consists of three separate pools that must never be merged: the legal CBD market (under 1 % THC, taxed and declarable), the medical market through pharmacies and prescriptions, and the grey or illegal recreational market. Adding those pools without separating their price levels produces the familiar billion-franc headlines that survive no scrutiny.

The methodologically clean route is bottom-up: consumption prevalence from the Swiss Health Survey, average annual consumption per user, then multiplication by the real street price per gram rather than a shop's aspirational price. For the CBD share, commercial-register entries (Zefix), the number of tobacco-tax registrants with the FOCBS and import statistics are the hardest data available. Municipal wastewater analysis adds an independent cross-check on consumption volume.

• Report three pools separately: legal CBD, medical, recreational – never a total without a breakdown.
• Use street prices, not shop prices; the gap skews estimates by a factor of 2–3.
• Zefix entries show company formations, not revenue.
• Use wastewater analysis as an independent check against self-report bias.

Economic dynamics of the pilot trials

The scientific pilot trials under Article 8b of the Narcotics Act (BetmG), which have been running for several years, provide the first real, state-controlled market data for THC cannabis in Switzerland. Projects such as Züri Can in Zurich or Weed Care in Basel enable the legal sale of recreational cannabis via pharmacies and social clubs. These time-limited studies serve as regulatory testing grounds to analyze consumer behavior, price acceptance, and the displacement of the illegal market under real-world conditions. The insights gained are crucial for the future design of a national Swiss cannabis market.

From an economic perspective, the pilot projects show how regulated supply chains behave, from agricultural production under organic guidelines to distribution to end consumers. The participating Swiss producers must comply with strict quality standards, which affects production costs compared to the black market. Since prices at the points of sale are closely aligned with the illegal market to create incentives for legal purchase, consumer price elasticity can be precisely measured. This data corrects previous theoretical market models and demonstrates the actual willingness to pay for certified quality.

• Regulatory basis provided by the experimental clause Article 8b of the Narcotics Act.
• Integration of pharmacies, social clubs, and specialized points of sale as distribution channels.
• Strict quality controls regarding pesticides, heavy metals, and exact THC content.
• Insights into the direct displacement of illegal street trade in the test areas.

The medical submarket after the amendment to the law

With the amendment to the law in August 2022, Switzerland fundamentally reorganized access to medical cannabis. The previously required, time-consuming exceptional authorization from the Federal Office of Public Health (BAG) was abolished, allowing doctors to prescribe corresponding preparations directly on their own responsibility. This liberalization has led to a noticeable market revitalization, as the administrative burden for medical professionals decreased drastically. Since then, demand has increasingly shifted from illegal self-medication to controlled, standardized medicinal products from pharmacies.

Despite the simplified access, the medical cannabis market in Switzerland remains shaped by regulatory requirements and quality standards from Swissmedic. The manufacture of medical cannabis is subject to the strict guidelines of Good Manufacturing Practice (GMP). Since the costs of cannabis-based medicines are usually only covered by health insurance companies under the mandatory basic insurance in justified individual cases upon request, financing remains a hurdle for many patients. This limits the short-term growth potential of this market segment compared to fully funded medicinal products.

• Abolition of the BAG exceptional authorization in August 2022 simplifies the prescription process.
• Responsibility of Swissmedic for the authorization and monitoring of standardized preparations.
• High quality requirements due to GMP guidelines make domestic production more expensive.
• Reimbursement by the compulsory health care insurance usually only occurs upon request on a case-by-case basis.

Regulatory hurdles and cost structures in the CBD trade

The Swiss market for CBD products with a total THC content of less than 1 percent is considered liberal by European standards, but is associated with significant regulatory costs. Since CBD flowers sold as tobacco substitutes are subject to the Swiss tobacco tax, manufacturers must pay high duties to the Federal Office for Customs and Border Security (BAZG). In addition, there are strict labeling requirements and monitoring by the Federal Food Safety and Veterinary Office (BLV), which restrictively regulates the use of CBD in food and cosmetics to rule out deception and health risks.

For Swiss CBD companies, these regulatory requirements lead to significant ongoing operating expenses. Each product batch must be tested in accredited laboratories for its exact cannabinoid content as well as the absence of harmful substances in order not to exceed the legal limit of 1 percent THC. Exceeding this limit immediately leads to classification as an illegal narcotic under the Narcotics Act (BetmG), resulting in criminal consequences and the confiscation of the commercial goods. These strict safety margins limit profit margins in the legal trade and lead to market consolidation to the detriment of capital-weak players.

• High tobacco tax on CBD flowers as tobacco substitute products by the BAZG.
• Restrictive requirements of the BLV regarding CBD in food and cosmetics.
• Mandatory laboratory analyses to ensure compliance with the legal THC limit of less than 1 percent.
• High financial risk due to product confiscation if limits are exceeded.

Cantonal differences in enforcement and their influence on the market

Although the Narcotics Act applies uniformly at the federal level, actual enforcement varies considerably across Swiss cantons. This particularly concerns the handling of minor quantities of THC cannabis for personal consumption. Adults caught with up to 10 grams of THC cannabis can be fined with a fixed penalty of 100 francs, whereby the consumption itself is fined, while mere possession can remain unpunished. Some cantons implement this regulation consistently and restrictively, while other authorities maintain a noticeably more liberal practice, leading to highly divergent regional risk profiles for consumers.

This federalist fragmentation also influences the local market structure and the collection of reliable economic data. In cantons with high control density and restrictive enforcement, illegal market actors increasingly shift to private spaces, making tracking via classic indicators such as seizures more difficult. In the legal CBD sector as well, cantonal laboratories and police authorities inspect points of sale with varying intensity. For market analyses, this means that cantonal data cannot simply be extrapolated to Switzerland as a whole, but must always be interpreted in the context of local enforcement practices.

• Federal differences in the enforcement of the 100-franc fixed penalty fine for adults.
• Cantonal laboratories monitor compliance with the 1% THC limit in retail with varying degrees of strictness.
• Regional differences in the density of police checks distort statistical records.
• Influence of cantonal practice on the choice of location for legal cannabis companies.

FAQ